Business
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Building on the commercial success of ORLADEYO® and the recent acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"image","alt":"BioCryst Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"BioCryst Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2oMvvMIKvjA9d_E4SRIeSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NA--/https://media.zenfs.com/en/globenewswire.com/9be0f0f5eacb522c15d80d31bd7eea85","width":300,"height":117}},"lazy":false},{"type":"text","content":"— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — ","length":126,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Sandeep M. Menon, MD, PhD, as Chief Research and Development Officer. Building on the commercial success of ORLADEYO® and the recent acquisition of Astria Therapeutics and the navenibart program, BioCryst is entering a new phase of execution in its strategy to build value through development and commercialization of rare disease therapies.","length":487,"tagName":"p"},{"type":"text","content":"Dr. Menon joins BioCryst from Alnylam Pharmaceuticals, where he served as Chief Development Officer, overseeing global clinical development and safety across a broad portfolio spanning multiple therapeutic areas. Under his leadership, his team read out and secured FDA approval of AMVUTTRA® (vutrisiran), a novel RNAi therapeutic for ATTR cardiomyopathy, and advanced multiple programs through key clinical milestones.","length":418,"tagName":"p"},{"type":"text","content":"“As BioCryst enters a critical phase, our priority is disciplined drug development and flawless regulatory delivery for innovative therapies that can change patients’ lives. Sandeep brings a proven record of leading complex programs through approval, scaling global R&D organizations, and making tough, value-driven decisions,” said Charlie Gayer, President and Chief Executive Officer of BioCryst. “With navenibart advancing toward a potential BLA and a growing pipeline behind it, his leadership strengthens our ability to sharpen our R&D strategy, balance capital allocation and risk, and create durable long-t...